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A B S T R A C T
Galectins constitute a family of β-galactoside-binding proteins (lectins) that are wide-
ly distributed in nature occurring in mammals, sponges, fungi, nematodes, insects 
and viruses. Galectins are involved in fundamental cellular processes in human skin 
and other tissues. They exert biological effects of considerable importance through 
interactions with cytoplasmic and nuclear proteins, as well as with components of cell 
surface and extracellular matrix. 
In this paper we summarize current knowledge on the expression of galectins 7 and 
9 in normal and diseased human skin and present the future perspectives of the use 
of these galectins or their antagonists/inhibitors in the diagnosis, prognosis and treat-
ment of cutaneous disorders.
I N T R O D U C T I O N
Galectins constitute a family of β-galactoside-binding proteins, most members of 
which possess one or two unique structures termed “conserved carbohydrate-recogni-
tion domains” (CRDs). These proteins are expressed in cells and tissues of humans and 
diverse organisms and reveal a high binding affinity for β-galactose in glucoconjugates, 
which depends on the structure of the latter and the possible modifications of galac-
tose residues, such as sialylation, fucosylation and sulfation.1,2 Seventeen mammalian 
galectins (12 occur in humans) have so far been identified, most of which consist of 
one CRD with about 130 amino acids, whereas a few others contain two homologous 
CRDs separated by a linker of up to 70 amino acids.1
Based on their structural properties, galectins can be classified into three major 
types (Figure 1): 
 a) The prototypical type (galectins 1, 2, 5, 7, 10, 11, 13, 14, 15, 16 and 17) which contains 
one single CRD that may associate to form homodimers.3
 b) The tandem-repeat type (galectins 4, 6, 8, 9 and 12) in which at least two CRDs oc-
curring within a single peptide linked by a small peptide domain possess different 
carbohydrate-binding affinities.2-4
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 c) The chimera type with galectin 3 as its sole representative. 
Apart from one CRD, this galectin contains a proline-rich 
collagen-like domain and a N-terminal domain.2,3
Galectins are synthesized in the ribosomes, are present in 
the cytoplasm and are translocated to the nucleus and other 
cellular compartments.5 Additionally, subsequent to their 
secretion via non classical pathways6, galectins can be found 
at the cell surface and in the extracellular environment.7 The 
expression and the distribution of galectins in the cytoplasm 
and the nucleus mainly depend on the type and the prolifera-
tive state of cells. Galectins are involved in a wide variety of 
significant molecular and cellular processes in both cutaneous 
and extracutaneous tissues and in the pathogenetic mecha-
nisms of diverse disorders.8
The purpose of this paper is to present current knowledge 
with regard to the expression of galectins 7 and 9 in normal and 
diseased human skin and to summarize the future perspectives 
of the use of these galectins and their antagonists/inhibitors in 
the diagnosis, prognosis and treatment of cutaneous disorders. 
The overview of the available data is based on the results of 
an electronic literature research that was conducted on the 
MEDLINE and SCOPUS databases until June 2018 using 
various combinations of the primary keyword “Galectins” 
with relevant terms, the most important of which were: kera-
tinocytes, Langerhans cells, Merkel cells, melanocytes, lym-
phocytes, macrophages, skin, human adult epidermis, human 
embryonic epidermis, keratinization, infection, inflammation, 
immune response, cutaneous angiogenesis, melanoma, cutane-
ous neoplasms, basal cell carcinoma, squamous cell carcinoma, 
keratoacanthoma, actinic keratosis, xanthoma, nevi, Bowen’s 
disease, tumor invasion and metastasis. 
G A l e C T I N  7
Galectin 7 (Gal 7) is a 14kDa one-CRD prototypical ga-
lectin encoded by the LGALS7 gene that is located on chro-
mosome 19. Gal 7 is mainly expressed in squamous stratified 
epithelia (keratinized or not), the outer root sheath of the hair 
follicle, the oral epithelia, the lips, the esophagus, the cornea, 
the Hassall’s corpuscles of the thymus and in myoepithelial 
cells from the mammary epithelia.9
Gal 7 functions extracellularly as a conventional galec-
tin, whereas intracellularly it is localized in the nucleus, the 
cytoplasm and the mitochondria. In the latter, it acts in a 
Bcl-2-dependent manner, sensitizing them to the apoptotic 
signal.10,11 In view of its proapoptotic activity, Gal 7 is regarded 
as a new molecular target for enhancement of the intrinsic 
apoptosis pathway.11 In more recent studies, however, it was 
found that Gal 7 is capable of causing not only promotion but 
also suppression of the apoptotic process depending on the cell 
type, the conditions of the microenvironment and the nature 
of the apoptotic stimuli.12
Gal 7 is secreted by proliferating, quiescent and differenti-
ated keratinocytes via a non-classical secretory pathway and is 
capable of suppressing proliferation in various cell lines.9,12 In 
Gal 7-null mice, the lack of expression of this galectin is associ-
ated with increased cell proliferation after epidermal injury or 
cutaneous irradiation with UVB.13 Tumor suppressor gene p53 
induces a marked upregulation of Gal 7 expression,14 whereas 
in human keratinocytes lacking the wild type p53 no induction 
of Gal 7 expression upon UVB irradiation is observed.15
The significance of Gal 7 as a differentiation marker of 
epidermal keratinocytes remains in dispute. Since this ga-
FIGURe 1. Classification of galectins.
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lectin is expressed in and secreted by proliferating basal and 
differentiated suprabasal keratinocytes,16-18 it is regarded by 
some authors as a marker of stratified epithelia but not as a 
differentiation marker.19 Nevertheless, its downregulation in 
keratinocyte cultures upon addition of retinoic acid and the 
increase of Gal 7 mRNA in relation to cell density14,16 sug-
gest that this galectin may also be associated with epidermal 
keratinocyte differentiation. More recently, Chen et al.20 
reported that Gal 7 is capable of regulating the proliferation 
and differentiation of epidermal keratinocytes through the 
JNK1-miR-203-p63 pathway.
Gal 7 exerts distinct effects on cellular adhesion and migra-
tion, processes of particular importance for wound healing, 
cancer progression and metastasis. It interacts with E-cadherin 
of adherent junctions in keratinocytes binding directly to its 
extracellular domain and leads to E-cadherin stabilization.13,19 
Interestingly, both absence or overexpression of Gal 7 cause an 
impairment of adherent junction-mediated adhesion.12,19 Gal 7 
may also be capable of regulating cell adhesion to extracellular 
matrix through interaction with β1-integrin and enhancement 
of matrix metalloproteinases expression.21-23
N O R m A l  h U m A N  S K I N
There are no data with regard to the occurrence of Gal 
7 in the embryonic human skin. In the adult normal human 
skin immunoreactivity for this galectin is found along the 
cell membrane of the cells in the basal and suprabasal layers, 
whereas the horny layer shows no Gal 7 expression.24 Distinct 
Gal 7 immunoreactivity is found in the basal cells of hair fol-
licles, the resident macrophages, the collagen fibrils of the 
dermis, the Langerhans cells, the extracellular matrix, the 
fibroblasts and the capillary walls.16,18,24-27 Interestingly, Lacina 
et al.28 found a positive cytoplasmic immunoreactivity for Gal 
7 in the keratinocytes in the basal and suprabasal layers but 
also in the stratum corneum of normal human epidermis with 
no signs of nuclear expression. Recently, Choi et al.29 found 
immunoreactivity for Gal 7 only in the cytoplasm of keratino-
cytes in normal epidermis and provided evidence suggesting 
that Gal 7 is a sensitive marker for differentiated and active 
keratinocytes in which its expression reveals a progressive 
age-dependent decrease.
C U T A N e O U S  N e O p l A S m S :
Α. Epithelial 
Data on the expression of Gal 7 in cutaneous epithelial 
neoplasms are conflicting and exclusively derived from studies 
on head and neck cancer. Magnaldo et al.18 detected immu-
noreactivity for Gal 7 in all cell layers of basal cell carcino-
mas (BCCs), although the labeling was less pronounced, as 
compared to that of normal epidermis; the intensity of Gal 7 
expression was lower in the basal and first suprabasal cell lay-
ers especially in BCCs.18 On the contrary, Cada et al.27 found 
no immunoreactivity for this galectin in BCCs. 
Gal 7 was barely detected by Magnaldo et al18 in squamous 
cell and spindle cell carcinomas, whereas other research groups 
found significantly high expression of this galectin in squamous 
cell carcinomas (SCCs) of the tongue, the buccal mucosa and 
the esophagus and suggested that Gal 7 may be involved in 
the mechanisms of oral carcinogenesis and may be regarded 
as marker of biological behavior and tumor progression.27,30-32 
Indeed, in oral SCCs, Gal 7 expression correlates with the 
histological malignancy grading system. In cultures of oral 
cancer cell lines, downregulation of this galectin results in a 
decrease of cell migration and invasion, whereas its overexpres-
sion exerts the opposite effects.12,33
B. Lymphomas
Moisan et al.34 were the first to report that upregulation of 
galectin-7 in murine lymphoma cells is associated with their 
progression toward an aggressive phenotype. Demers et al.35 
reported that stable transfection of lymphoma cells with a 
plasmid encoding antisense Gal 7 cDNA caused a significant 
inhibition of dissemination and invasion of lymphoma cells to 
peripheral organs. Moreover, inhibition of Gal 7 in aggressive 
lymphoma cells correlates with the decrease in their invasion 
in target organs and the reduced expression of matrix metal-
loproteinase-9, which is known to be induced by Gal 7 in 
mouse and human lymphoma cells.36 These authors also found 
an upregulation of Gal 7 levels in most investigated B-cell 
lymphoid malignancies but not in normal B lymphocytes. This 
upregulation of Gal 7 in lymphoma cells does not depend on 
p53 but is rather related to alterations in DNA methylation.37 
Based on their findings, these authors suggested that Gal 7 
may serve as a potential therapeutic target in the treatment 
of lymphoid malignancies. 
C. Melanomas 
Gal 7 at the mRNA level was detected in more than 90% of 
skin biopsies obtained from patients with nevi; however, in situ 
labeling showed that Gal 7 immunoreactivity in these biopsies 
was likely due to that of the surrounding keratinocytes. Gal 
7 expression was rarely found in skin biopsies derived from 
patients with malignant melanoma.38 Gal 7 caused a reduction 
in the motility of B16F1 experimental melanoma cells, an 
increase in their resistance to apoptosis and an upregulation 
of early growth response protein 1 (EGR-1). Gal 7 ectopic 
expression was not capable of affecting either the growth of 
the tumors induced by the injection of B16F1 or their metas-
tasis to the lungs.38
m I S C e l l A N e O U S :
Cutaneous amyloidosis
It is well known that Gal 7 is a component of amyloid fibrils 
and contains considerable amounts of β-sheet structure. Miura 
et al.39 detected this galectin by immunoblot assay in the water-
soluble fractions prepared from the lesional skin of patients 
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with primary localized cutaneous amyloidosis. Moreover, they 
found Gal 7 immunoreactivity in tumor-associated localized 
cutaneous amyloidosis, whereas the dermis in the apparently 
normal skin of the patients was negative for this galectin. 
Since Gal 7 is overexpressed in apoptotic keratinocytes 
and amyloid deposit is related to keratinocyte apoptosis, 
Gal 7 was considered as a possible candidate amyloidogenic 
protein.39 Interestingly, the findings of the study of Ono et 
al.40 provided evidence suggesting that in primary localized 
cutaneous amyloidosis (PLCA) the mechanism of amyloi-
dogenesis includes the following steps: a. Induction of Gal 7 
expression and activation of proteases related to the apoptotic 
process. b. Release of tryptic peptides at neutral conditions. 
c. Aggregation of amyloidogenic peptides in acidified pH that 
is modulated by Gal 7 peptides, actin and cytokeratins and d. 
Formation of amyloid fibrils by deposition of Gal 7 fragments. 
Further studies are now warranted to define the nature of 
Gal 7 peptides that participate in cutaneous amyloidogenesis 
and to answer the question as to whether this galectin might 
be a useful therapeutic target for the management of PLCA. 
Wounds and scars
In patients with hypertrophic scars Gal 7 is markedly 
downregulated in both the skin and the serum.41 The inten-
sity of Gal 7 immunoreactivity in scars is localized along the 
cytoplasmic membrane of the basal and suprabasal cells and 
in the extracellular space of the papillary dermis, as well.41 By 
means of ablative laser treatment, Cho et al (2013)41 induced 
wound healing in healthy control tissue and demonstrated an 
uniformly intensive cytoplasmic staining of keratinocytes in 
the epidermis and the follicular outer sheath; during wound 
healing, they found a strong cytoplasmic membrane immu-
noreactivity of keratinocytes for Gal 7 at days 3, 5, 14 and 21 
and of the upper papillary dermis at days 1, 3 and 10. Based 
on their findings, these authors suggested that the observed 
differences between control skin and hypertrophic scars with 
regard to the expression and subcellular/extracellular distribu-
tion of Gal 7 indicate that this galectin may play an important 
role in the pathogenetic mechanisms underlying the unbal-
anced scar formation. 
In experimental studies it has been shown that Gal 7 can 
also regulate the migration of epithelial cells during wound 
healing subsequent to epidermal injury.42 Indeed, re-epithelial-
isation in Gal 7-null mice was delayed, as compared to that seen 
in wild type mice without any difference in cell proliferation 
between the two groups. These findings indicate that the effects 
of Gal 7 on epidermal wound healing are due to the induced 
enhancement of keratinocyte migration and are not related 
to cell proliferation. This view is supported by the results of 
recent in vitro studies that showed a decrease in migration 
speed and efficiency in galectin-7-depleted keratinocytes 
(HaCaT cells).19 Further studies are now warranted to assess 
the possible therapeutic potential of Gal 7 in the management 
of cutaneous wounds. 
G A l e C T I N  9
Human galectin 9 (Gal 9) is a 34-39 kDa tandem-repeat 
type protein encoded by the LGALS9 gene, that is located on 
chromosome 17q11.2.43 Gal 9 contains two non-homologous 
N- and C-terminal CRDs connected by a linker peptide.44 
Gal 9 is found in a wide spectrum of human tissues and cell 
types including the skin, liver, spleen, small intestine, thymus, 
kidneys, lung, cardiac and skeletal muscles, brain, pancreas, 
placenta, prostate, colon, lymph nodes and peripheral blood 
leukocytes.45
Gal 9 reveals extracellular and intracellular distribution.46 
Extracellular Gal 9 is released from diverse cells via the non-
classical pathways and can mediate, among others, processes 
such as cell adhesion and cell surface recognition, cell aggrega-
tion, cell-cell and cell-extracellular matrix interactions, migra-
tion, chemoattraction, receptor endocytosis, lipid recycling and 
raft clustering.43,47 Intracellular Gal 9 can mediate mechanisms 
underlying signal transduction, development, growth, im-
mune response and apoptosis.48 Furthermore, this galectin 
is capable of regulating differentiation45 and proliferation in 
diverse cell types49 and of inducing concentration-dependent 
immunomodulation particularly through apoptosis of specific 
T cell subpopulations that are associated with autoimmunity, 
inflammation and graft rejection.50,51
N O R m A l  h U m A N  S K I N 
To the best of our knowledge, no data are available so far 
on the expression of Gal 9 in human embryonic skin. In normal 
adult human skin Cada et al.27 observed a strong Gal 9 immu-
noreactivity in the keratinocytes of the basal layer and a weak 
one in those of the suprabasal layers. A weak positive Gal 9 
immunoreactivity was also observed by de la Fuente et al.52 in 
epidermal keratinocytes, Langerhans cells and dendritic cells 
of normal human skin, whereas dermal fibroblasts strongly 
expressed this galectin.44
C U T A N e O U S  A N D  S y S T e m I C  D I S O R D e R S :
Psoriasis 
Although psoriasis represents the most common keratini-
zation disorder, data on the expression of galectins in psoriatic 
lesions and their possible involvement in the pathogenetic 
mechanisms of this disease are sparse. De la Fuente et al.52 
found no significant differences between the lesional and the 
apparently normal skin of psoriatic patients and the skin of 
healthy controls with regard to the levels of Gal 9 mRNA 
expression. Recently, Igawa et al.44 reported that there is a 
weak expression of Gal 9 in keratinocytes obtained from the 
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middle and upper layers of psoriatic epidermis, whereas der-
mal fibroblasts reveal a significant expression of this galectin. 
Gal 9 is a physiological ligand of Tim-3, a cell surface 
molecule preferentially expressed on Th1 and Th17 cells.53 In 
psoriasis, the expression of Tim-3 on these cells is impaired 
allowing them to escape from Tim-3-mediated negative 
regulatory system and to contribute to the pathogenesis of 
this disease.54 Niwa et al.55 developed a stable form of Gal 
9 that is resistant to natural proteolytic inactivation and ad-
ministered it to the IL-23-induced psoriatic mouse model. In 
the Gal 9-treated animals they observed a marked reduction 
of epidermal thickness, dermal cellular infiltrate and of the 
levels of IL-17 and IL-22 in the lesional skin. Although these 
experimental findings cannot be directly extrapolated to the 
human conditions, they do support, however, the hypothesis 
that Gal 9 may be a novel and promising agent for the treat-
ment of psoriasis and other cutaneous disorders with Th1 and 
Th-17 mediated skin inflammation.55
Atopic dermatitis 
Atopic dermatitis is a cutaneous allergic disorder char-
acterized by peripheral eosinophilia, mast cell activation and 
predominance of Th2 cells.56 In patients with atopic dermatitis, 
Gal 9 immunoreactivity is detected in epidermal keratinocytes 
and mast cells, which are also its main source in the lesional 
skin; the intensity of the expression is stronger, as compared 
to that in normal skin and is also evident in some infiltrating 
mast cells in the upper dermis.56 Additionally, the levels of Gal 
9 are elevated in the serum of patients with atopic dermatitis, 
as compared to healthy controls; these levescorrelate with 
the area of eczematous lesions and their severity index and 
decrease after treatment. These results indicate that Gal 9 
may be used as a clinical marker of the severity of the disease 
and suggest that the Th2-polarized microenvironment in the 
lesional skin of patients with atopic dermatitis induces a Gal 
9 upregulation and consequently exacerbation of Th2 po-
larization through accumulation of mast cells, after possible 
interaction of the latter with the epidermal keratinocytes.56 In 
view of these effects, it seems reasonable to assume that Gal 9 
may represent a novel therapeutic target in the management 
of atopic dermatitis. 
Systemic scleroderma
It is well known that in patients with systemic scleroderma 
dermal fibroblasts promote skin-localized transdifferentiation 
of regulatory T cells to T helper (Th) type 2-like cells. Nev-
ertheless, the exact mechanisms underlying the interaction of 
dermal fibroblasts with immune cells in this disease remain 
to be elucidated. In view of the capability of Gal 9 to induce 
Th2 cytokine-predominant immune imbalance by negative 
regulation of Th1/Th17 cells, Saigusa et al.57 investigated the 
contribution of Gal 9 to Th immune balance in the lesional 
skin of patients with systemic scleroderma and found that 
this galectin was overexpressed in the dermal fibroblasts of 
the patients in vivo and in vitro, whereas serum Gal 9 levels 
were significantly elevated and positively correlated with skin 
score. These authors provided evidence suggesting that dermal 
fibroblasts derived from patients with systemic scleroderma 
suppress interferon-γ expression of skin-infiltrating CD4+ T 
cells through Gal 9 overproduction and promote skin fibrosis.55 
The question as to whether administration of Gal 9 inhibitors/
antagonists may be a novel approach to the treatment of sys-
temic scleroderma remains to be elucidated in future studies. 
C U T A N e O U S  N e O p l A S m S
Epithelial
Apart from the study of Cada et al.27, who observed a weak 
to moderate Gal 9 immunoreactivity in basal cell carcinomas, 
all available data on the expression of this galectin in epithelial 
neoplasms originate from studies on SCCs of the head and 
neck region and are conflicting. In contrast to the normal 
mucosa that revealed Gal 9 expression in the epithelial cells 
of the basal layer, all tested oral SCCs were completely devoid 
of any immunoreactivity for Gal 9 in the epithelial tumor 
cells.58 This finding was interpreted by the authors as a result 
of microenvironment alterations occurring during the process 
of tissue dysplasia up to malignant transformation. 
On the contrary, Muniz et al.59 found increased immunore-
activity for Gal 9 in oral SCCs, as compared to normal mucosa 
and leukoplakia and suggested that the significant expression 
of Gal 9 in these tumors may be helpful for their differentia-
tion from other oral cavity lesions.
Melanomas
Gal 9 expression is downregulated in primary melanomas, 
as compared to melanocytic nevi, whereas metastatic melano-
mas exhibit minimal or no immunoreactivity for this galectin.60. 
In primary melanomas, immunoreactivity is mostly detected 
in the cytoplasm of melanoma cells and in some cases also 
in the nucleus. In addition, most melanoma cells exhibiting 
nest formation reveal an increased cytoplasmic expression, as 
compared to those with little or without nest formation, thus, 
suggesting that Gal 9 may play a significant role in the mecha-
nisms underlying the nest formation of melanocytic cells.60
Since patients with melanoma demonstrating high Gal 9 
expression show significantly lower rates of lymph node me-
tastasis, recurrence and death than those with low expression 
of this galectin, Kageshita et al.60 put forth the hypothesis that 
high Gal 9 expression in primary melanomas is associated with 
a better prognosis. Interestingly, in experimental studies it has 
been shown that Gal 9 suppresses melanoma metastasis by 
blocking the adhesion of malignant cells to endothelium and 
extracellular matrices, whereas loss of its expression is closely 
associated with metastatic progression of melanoma.61
24
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Human recombinant Gal 9 [Gal 9 (0)] is resistant to prote-
olysis, since it is devoid of the peptide that links its two CRDs. 
Gal 9(0) was found to exert distinct and previously unrecog-
nized cytotoxic effects on melanoma cells in vitro by causing 
their rapid apoptotic death.62 Based on this finding, it has been 
suggested that Gal 9(0) may represent a novel therapeutic 
agent for the management of human metastatic melanoma.62
In view of the negative regulation of Th1 immune response 
by Gal 9, which promotes Th2 type immunity favoring tumor 
development63, Enninga et al.64 studied the effects of this 
galectin on the immune response of patients with metastatic 
melanoma. They found a high expression of Gal 9 at the 
melanoma tumor edge and a significant (3.6-fold) increase in 
the plasma Gal 9 levels of patients, as compared to healthy 
controls. Interestingly, the latter finding was associated with 
systemic Th2 polarization and worse survival rate (independent 
from clinical factors), as compared to that of patients with a low 
or no increase in Gal 9 plasma levels. These findings suggest 
that plasma levels of Gal 9 may be regarded as a prognostic 
marker in metastatic melanoma and that this galectin may rep-
resent a novel therapeutic target of immunotherapy in order 
to achieve a recovery of Th1 tumor targeting immune state64. 
In view of these discrepancies and the complexity of Gal 
9 biological actions, it is clear that further studies are now 
warranted in order to a. define the role played by the immu-
nomodulatory, antiadhesive and pro-apoptotic effects of Gal 
9 in the mechanisms of melanoma growth and metastasis and 
b. accurately assess the therapeutic potential of this galectin 
or its inhibitors in the management of melanoma.
h I v - I N F e C T I O N
Gal 9 is known to cause a reduction of Th1 and Th17 cells 
and an increase of anti-inflammatory regulatory T cells. In 
chronic HIV-1 infection, plasma levels of this galectin were 
found to correlate with HIV-1 viral load.65 In patients with 
acute HIV infection plasma levels of Gal 9 were extremely 
elevated (50-fold) but revealed a rapid and marked decrease 
after treatment.66 This rapid decline may be associated with 
clinical amelioration, since Gal 9 interacts with Tim-3 ex-
pressed on the surface of activated CD4(+) T cells and reduces 
their susceptibility to HIV-1 infection and replication.65 Based 
on this finding, the authors suggested that plasma levels of Gal 
9 may predict a severe inflammation status during the acute 
phase of HIV-1 infection and represent a potential biomarker 
of this disorder during its acute phase.
Abdel-Mohsen et al.67 found out that administration of re-
combinant Gal 9 reverses HIV latency in both, an experimental 
model in vitro and in primary CD4+ T cells ex vivo obtained 
from HIV-infected, through antiretroviral therapy (ART) 
immunosuppressed individuals. These authors suggested that 
Gal 9 is capable of regulating HIV transcription and viral 
production in vivo during therapy and that Gal 9 manipulation 
through modulation of endogenous production or exogenous 
administration of the recombinant protein may significantly 
contribute to the development of novel therapeutic or even 
curative approaches to HIV infection. 
C O N C l U S I O N S
Galectins are small and highly conserved proteins that are 
widely distributed in nature, bind to a variety of glycoproteins 
and glycolipids bearing β-galactoside residues and interact 
with diverse non-glycosylated molecules within the nucleus 
and the cytoplasm.
Galectins 7 and 9, representatives of the prototypical and 
tandem-repeat type of galectins, respectively, are involved 
in diverse fundamental molecular and cellular processes oc-
curring in cutaneous and extracutaneous tissues including 
proliferation, apoptosis, differentiation, immune and inflam-
matory response, tumor cell growth, migration, invasion, and 
metastasis.
Disturbances in the distribution and expression of Gal 7 
and Gal 9 found in a variety of cutaneous disorders may be 
involved in their pathogenesis. Accumulating experimental 
and clinical evidence strongly suggests that the administration 
of these galectins or their inhibitors/antagonists may open up 
entirely new avenues in the treatment of various cutaneous 
disorders (e.g. lymphomas, lichen amyloidosus, wounds, pso-
riasis, atopic dermatitis, systemic scleroderma, melanoma and 
HIV-infection). Further data may provide a more thorough 
understanding of the mechanisms involved in the pathogenesis 
of several cutaneous diseases, as well as the processes underly-
ing the biological function of Gal 7 and Gal 9.
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